Premium
A Biodegradable Polymersome Containing Bcl‐xL siRNA and Doxorubicin as a Dual Delivery Vehicle for a Synergistic Anticancer Effect
Author(s) -
Kim HyunOuk,
Kim Eunjung,
An Yonghee,
Choi Jihye,
Jang Eunji,
Choi Eun Bi,
Kukreja Aastha,
Kim MyeongHoon,
Kang Byunghoon,
Kim DongJoo,
Suh JinSuck,
Huh YongMin,
Haam Seungjoo
Publication year - 2013
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201200448
Subject(s) - polymersome , nanocarriers , doxorubicin , chemistry , cytotoxicity , ethylene glycol , drug delivery , small interfering rna , pharmacology , anticancer drug , gene delivery , drug , genetic enhancement , copolymer , biochemistry , chemotherapy , in vitro , transfection , medicine , gene , amphiphile , organic chemistry , surgery , polymer
Combined cancer treatment via co‐delivery of siRNAs and an anticancer drug can be a promising strategy due to the synergistic effect of simultaneously minimizing gene/drug administration. In this study, Bcl‐xL siRNA and doxorubicin (DOX) are encapsulated into designed methoxy‐poly(ethylene glycol)‐ block ‐poly( D , L ‐lactic acid) (mPEG‐ b ‐PLA) block copolymer polymersomes (PSomes). A study of the cytotoxicity of Bcl‐xL siRNA and DOX co‐encapsulated PSomes (CPSomes) shows more inhibited proliferation of MKN‐45 and MKN‐28 human gastric cancer cell lines than only gene‐ and drug‐loaded ones. Consequently, these results demonstrate that co‐delivery of genes and drugs using PSomes results in a synergistic efficacy and indicates the potential of PSomes as efficient nanocarriers for combined cancer therapy.